These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3404742)

  • 1. [Prediction of postpartum relapse of Graves' thyrotoxicosis and the development of neonatal Graves' disease by the highly sensitive TSH immunoradiometric assay].
    Takeoka K; Amino N; Tamaki H; Aozasa M; Tachi J; Iwatani Y; Mori M; Tanizawa O; Miyai K
    Rinsho Byori; 1988 Apr; 36(4):455-8. PubMed ID: 3404742
    [No Abstract]   [Full Text] [Related]  

  • 2. [Development of neonatal Graves' disease--prediction, prevention and treatment].
    Matsuura N
    Nihon Rinsho; 2006 Dec; 64(12):2303-7. PubMed ID: 17154096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of thyrotropin-releasing hormone (TRH) test with a sensitive immunoradiometric thyrotropin (TSH) assay kit].
    Nakamura S; Demura R; Yamanaka Y; Ishiwatari N; Jibiki K; Odagiri E; Demura H
    Kaku Igaku; 1987 Oct; 24(10):1565-72. PubMed ID: 3441064
    [No Abstract]   [Full Text] [Related]  

  • 4. [Laboratory diagnosis before onset and prediction of Graves' disease].
    Hidaka Y; Tada H; Amino N
    Rinsho Byori; 1997 Sep; 45(9):825-30. PubMed ID: 9311254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fundamental studies on thyroid stimulating hormone immunoradiometric assay kit (TSH RIABEAD II)].
    Muraki H; Tsutsui K; Sato K; Toyama O; Nakazawa M; Niizuma S
    Radioisotopes; 1987 Jan; 36(1):24-7. PubMed ID: 3562907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical experience of a sensitive immunoradiometric thyrotropin assay kit (RIA-gnost hTSH)].
    Nakamura S; Jibiki K; Demura R; Koike S; Kurihara S; Odagiri E; Demura H
    Kaku Igaku; 1987 Mar; 24(3):335-40. PubMed ID: 3613276
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy insight: management of Graves' disease during pregnancy.
    Chan GW; Mandel SJ
    Nat Clin Pract Endocrinol Metab; 2007 Jun; 3(6):470-8. PubMed ID: 17515891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
    Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thyroid stimulating antibodies in pregnant women with Graves' disease and neonatal thyrotoxicosis].
    Nygaard B; Petersen JR; Jespersen NF
    Ugeskr Laeger; 1997 Feb; 159(8):1086-9. PubMed ID: 9072852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foetal and neonatal thyroid disorders.
    Radetti G; Zavallone A; Gentili L; Beck-Peccoz P; Bona G
    Minerva Pediatr; 2002 Oct; 54(5):383-400. PubMed ID: 12244277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
    Bayer MF; Kriss JP; McDougall IR
    J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of TSH receptor antibody determination].
    Gannage MH; Haddad F; Jambart S; Atallah C; Halaby G
    J Med Liban; 1996; 44(3):134-7. PubMed ID: 9296963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid cancer yield in patients with Graves' disease.
    Stocker DJ; Burch HB
    Minerva Endocrinol; 2003 Sep; 28(3):205-12. PubMed ID: 14605602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyrotropin receptor autoantibodies in Graves' disease.
    Schott M; Scherbaum WA; Morgenthaler NG
    Trends Endocrinol Metab; 2005 Jul; 16(5):243-8. PubMed ID: 15950483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal hypothyroxinemia with normal thyrotropin. Clue to maternal Graves' disease.
    Slyper AH; Shaker JL
    Clin Pediatr (Phila); 1993 Feb; 32(2):121-3. PubMed ID: 8094332
    [No Abstract]   [Full Text] [Related]  

  • 20. IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C. Case report.
    Duncea I; Pepene CE
    J Gastrointestin Liver Dis; 2008 Dec; 17(4):453-6. PubMed ID: 19104709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.